Yang Peini, Shan Bin, Hu Xing, Xue Li, Song Guibo, He Pingan, Yang Xu
Department of Clinical Laboratory, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Department of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, China.
J Bacteriol. 2025 Apr 17;207(4):e0038724. doi: 10.1128/jb.00387-24. Epub 2025 Mar 26.
Carbapenem-resistant (CRKP) is a clinical pathogen with a high mortality rate, and its clinical management and infection control have become a serious challenge. Phage-encoded depolymerase cleaves the capsular polysaccharide, a major virulence factor of . This study aimed to identify a phage depolymerase targeting ST11 K64 CRKP, evaluate its antimicrobial activity and therapeutic efficacy, and provide new alternative therapeutic strategies for K64 CRKP. Phages were screened from untreated hospital sewage using clinically isolated CRKP as the host bacterium. The host range, efficiency of plaque formation, optimal multiplicity of infection, adsorption efficiency, and one-step growth curve of phage vB_KpnP_IME1309 were determined by the double-layer agar plate culture method. The morphology of the phage was observed by transmission electron microscopy. Phage nucleic acids were extracted for whole-genome sequencing, and the phage-encoded depolymerase gene ORF37 was amplified by polymerase chain reaction. Next, a recombinant plasmid was constructed to induce depolymerase expression, which was verified using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. bactericidal activity was determined using a combined serum assay, and the anti-. biofilm effect of depolymerase was determined by crystal violet staining. Finally, a larvae infection model was established to investigate the therapeutic effect of depolymerase on larvae . Here, we isolated and characterized a phage vB_KpnP_IME1309 targeting ST11 K64 CRKP, which featured a latent period of 20 min and a burst size of approximately 290 plaque-forming units/cell. It contained 41 predicted open reading frames, of which ORF37 encoded depolymerase. The expressed and purified depolymerase Dep37 cleaved only ST11 K64 CRKP and formed a translucent halo on the agar plate. Dep37 increased the susceptibility of B1 to serum killing, inhibited CRKP biofilm formation, and degraded mature biofilms. The combination of Dep37 and kanamycin was significantly more effective in treating CRKP biofilms compared to either Dep37 or kanamycin alone. An injection of Dep37 at 5 min and 2 h after the CRKP infection of larvae increased their survival rates by up to 73% and 53%, respectively. Depolymerase Dep37 may be used as a potential method for capsule typing of , showing great promise for the development of novel alternative therapeutic strategies against ST11 K64 CRKP.
A novel phage vB_KpnP_IME1309 targeting ST11 K64 carbapenem-resistant (CRKP) was isolated and characterized. The ORF37 encoding depolymerase gene of phage vB_KpnP_IME1309 was successfully expressed and purified. Depolymerase increases the susceptibility of CRKP to serum killing, inhibits CRKP biofilm formation, and degrades mature biofilms. The combination of depolymerase and kanamycin is significantly more effective than either depolymerase or kanamycin alone in the treatment of CRKP biofilm. Depolymerase injection at 5 min and 2 h after CRKP infection of larvae increased the survival rate of larvae by up to 73% and 53%, respectively. Depolymerase Dep37 may be used as a method for the development of novel alternative therapeutic strategies against ST11 K64 CRKP.
耐碳青霉烯类肺炎克雷伯菌(CRKP)是一种死亡率很高的临床病原体,其临床管理和感染控制已成为一项严峻挑战。噬菌体编码的解聚酶可裂解荚膜多糖,这是肺炎克雷伯菌的一种主要毒力因子。本研究旨在鉴定一种靶向ST11 K64 CRKP的噬菌体解聚酶,评估其抗菌活性和治疗效果,并为K64 CRKP提供新的替代治疗策略。以临床分离的CRKP作为宿主菌,从未经处理的医院污水中筛选噬菌体。采用双层琼脂平板培养法测定噬菌体vB_KpnP_IME1309的宿主范围、噬斑形成效率、最佳感染复数、吸附效率和一步生长曲线。通过透射电子显微镜观察噬菌体的形态。提取噬菌体核酸进行全基因组测序,并通过聚合酶链反应扩增噬菌体编码的解聚酶基因ORF37。接下来,构建重组质粒以诱导解聚酶表达,并用十二烷基硫酸钠-聚丙烯酰胺凝胶电泳进行验证。使用联合血清试验测定杀菌活性,并测定解聚酶的抗生物膜作用。最后,建立幼虫感染模型以研究解聚酶对幼虫的治疗效果。在此,我们分离并鉴定了一种靶向ST11 K64 CRKP的噬菌体vB_KpnP_IME1309,其潜伏期为20分钟,裂解量约为290个噬斑形成单位/细胞。它包含41个预测的开放阅读框,其中ORF37编码解聚酶。表达并纯化的解聚酶Dep37仅裂解ST11 K64 CRKP,并在琼脂平板上形成半透明晕圈。Dep37增加了肺炎克雷伯菌B1对血清杀伤的敏感性,抑制CRKP生物膜形成,并降解成熟生物膜。与单独使用Dep37或卡那霉素相比,Dep37与卡那霉素联合使用在治疗CRKP生物膜方面明显更有效。在幼虫感染CRKP后5分钟和2小时注射Dep37分别使幼虫存活率提高了73%和53%。解聚酶Dep37可作为肺炎克雷伯菌荚膜分型的一种潜在方法,在开发针对ST11 K64 CRKP的新型替代治疗策略方面显示出巨大潜力。
分离并鉴定了一种靶向ST耐碳青霉烯类肺炎克雷伯菌(CRKP)的新型噬菌体vB_KpnP_IME1309。成功表达并纯化了噬菌体vB_KpnP_IME1309编码解聚酶的基因ORF37。解聚酶增加了CRKP对血清杀伤的敏感性,抑制CRKP生物膜形成,并降解成熟生物膜。在治疗CRKP生物膜方面,解聚酶与卡那霉素联合使用明显比单独使用解聚酶或卡那霉素更有效。在幼虫感染CRKP后5分钟和2小时注射解聚酶分别使幼虫存活率提高了73%和53%。解聚酶Dep37可作为开发针对ST11 K64 CRKP的新型替代治疗策略的一种方法。